Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial
20 Octubre 2021 - 6:00AM
Synairgen
plc(‘Synairgen’ or the ‘Company’)
Synairgen
announces its inhaled
interferon beta (SNG001)
is advancing to
Phase 3 of the
NIH-sponsored ACTIV-2
COVID-19 Trial
Southampton, UK – 20 October 2021: Synairgen plc
(LSE: SNG), the respiratory company developing SNG001, a
formulation for inhalation containing the broad-spectrum anti-viral
protein interferon beta (IFN-beta) for the treatment of severe
viral lung infections, has been informed that the external data
safety monitoring board (DSMB) of the ACTIV-2 study has recommended
that SNG001 advance into Phase 3 in mild to moderate COVID-19
patients.
Phillip Monk, Chief Scientific Officer
of Synairgen, explained:
“Interferon beta is a naturally-occurring protein, which
orchestrates the body's antiviral responses. SARS-CoV-2 suppresses
IFN-beta production to compromise the immune system; the aim of
delivering SNG001 directly into the lungs is to restore or boost
natural antiviral defences to prevent the virus from causing severe
lower respiratory tract illness. Unfortunately, despite vaccination
programmes and early interventions, thousands of patients are still
hospitalised every day due to COVID-19-induced breathing
difficulties. Data to date suggests SNG001 is well tolerated with a
favourable safety profile and there is growing evidence to support
the rationale for delivering IFN-beta directly into the lungs to
counter the effects of SARS-CoV-2.”
Richard Marsden, CEO of Synairgen,
said: “The advancement of SNG001 from Phase 2 to Phase 3
of the large ACTIV-2 trial is very welcome news and continues to
build the case that our formulation of inhaled IFN-beta may have an
important role in combatting COVID-19 and future emerging virus
threats. In addition to the ACTIV-2 trial, our own Phase III
SPRINTER study assessing SNG001 in hospitalised COVID-19 patients,
is also progressing well and we expect top-line results in early
2022.”
As of today, Synairgen has not received any data
from the ACTIV-2 trial.
Accelerating COVID-19 Therapeutic Interventions
and Vaccines (ACTIV) is a public-private partnership to develop a
coordinated research strategy to accelerate the development of the
most promising COVID-19 treatments and vaccines. ACTIV-2 is
testing agents in non-hospitalised adults experiencing mild to
moderate COVID-19 and is sponsored by NIAID, part of the National
Institutes of Health, and is led by the NIAID-funded AIDS Clinical
Trials Group (ACTG). To read more about ACTIV-2, visit their
website here.
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU) No. 596/2014
(‘MAR’).
For further enquiries, please contact:
Synairgen plcRichard Marsden, Chief Executive
OfficerJohn Ward, Chief Financial OfficerBrooke Clarke, Head of
CommunicationsBrooke.Clarke@synairgen.comTel: + 44 (0) 23 8051
2800
finnCap (NOMAD and Joint Broker)Geoff Nash,
Kate Bannatyne, Charlie Beeson (Corporate Finance)Alice Lane, Sunil
de Silva (ECM)Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)James
Black, Freddie Barnfield, Duncan MonteithTel: + 44 (0) 20 7260
1000
Consilium Strategic Communications (Financial Media and
Investor Relations)Mary-Jane Elliott, Jessica Hodgson,
Lucy Featherstone synairgen@consilium-comms.comTel: +44 (0) 20 3709
5700
MKC STRATEGIES, LLC (US Media Relations)Mary
ConwayMConway@MKCStrategies.comTel: +1 516-606-6545
Notes for Editors
About Synairgen Synairgen is a
UK-based respiratory company focused on drug discovery, development
and commercialisation. The Company’s primary focus is developing
SNG001 (inhaled interferon beta) for the treatment of COVID-19 as
potentially the first host-targeted, broad-spectrum antiviral
treatment delivered directly into the lungs. Granted Fast Track
status from the US Food and Drug Administration (FDA) and deemed an
Urgent Public Health study by the UK's National Institute for
Health Research (NIHR), Synairgen’s Phase III clinical programme is
currently evaluating nebulised SNG001 in patients across 17
countries. In a Phase II trial in hospitalised COVID-19 patients,
SNG001 demonstrated a greater than two-fold chance of recovery to
‘no limitation of activities’ versus placebo.1
Founded by University of Southampton Professors
Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003,
Synairgen is quoted on AIM (LSE: SNG). For more information about
Synairgen, please see www.synairgen.com.
1 –
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024